

# Latestage chronic kidney disease (CKD) - Pipeline Review, 2019

<https://marketpublishers.com/r/L321BA4FB971EN.html>

Date: November 2019

Pages: 120

Price: US\$ 1,250.00 (Single User License)

ID: L321BA4FB971EN

## Abstracts

Firstview Insight's Latestage chronic kidney disease (CKD) - Pipeline Review, 2019 provides an overview of the pipeline landscape of Latestage chronic kidney disease (CKD) It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc. These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.

Chronic kidney disease (CKD) refers to all five stages of kidney damage, from very mild damage in stage 1 to complete kidney failure in stage 5. Kidney failure, also called end-stage renal disease (ESRD), is the last stage of chronic kidney disease. When your kidneys fail, it means they have stopped working well enough for you to survive without dialysis or a kidney transplant. The stages of kidney disease are based on the eGFR number (Stage 1 CKD: eGFR 90 or Greater, Stage 2 CKD: eGFR Between 60 and 89, Stage 3 CKD: eGFR Between 30 and 59, Stage 4 CKD: eGFR Between 15 and 29, Stage 5 CKD: eGFR Less than 15). Chronic kidney failure results in loss of kidney function over months or years. In advanced stages, dangerous levels of wastes and fluids back up in your body. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles.

The economic burden of CKD is substantial. According to the US Renal Data System, in 2013 among fee-for-service Medicare patients, total medical costs were \$50.4 billion for CKD (excluding end-stage renal disease [ESRD]), and another \$30.9 billion for the ESRD patient population.

Factors propelling the chronic kidney disease market growth includes growing incidences of diabetes and cardiovascular disorders, increasing prevalence of CKD, promising pipeline molecule, significant unmet needs, and rising geriatric population.

Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Amgen, Asahi Kasei Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer and Sanofi etc.

There are ~65 drugs under development for this indication. Promising pipeline molecule such as ABT-614 (Abbott laboratories), EOS789 (Chugai Pharmaceutical)

## **LIST OF PRODUCTS**

LNP023

AB002

Veverimer

jtz-951

Desidustat

Roxadustat

KBP-5074

Ziltivekimab

DM199

CTAP101

Finerenone

DDO-3055

RBT-1

BI 764198

Bemethyl

Regenerative medicine program-UNICYTE

### **Drug Profile Overview:**

The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.

### **Clinical Trial Overview:**

This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.

### **Product Development Activity:**

This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.

### **Company Overview:**

Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial

## **Scope**

The report provides a competitive landscape

The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status

The report provides the list of companies which are the most active in the pipeline

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery

The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities

The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)

The report summarizes all the dormant and discontinued pipeline projects

The report also provides latest news for the past one year

## **Reasons To Buy**

To identifying prominent players in the treatment landscape

To determine the drivers; barriers and unmet need in the treatment space

Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies

Define in-licensing and out-licensing strategies by identifying prospective

partners with the most attractive projects to enhance and expand business potential and scope

To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration

## Contents

### **1. DISEASE OVERVIEW**

- 1.1. Pathophysiology
- 1.2. Symptoms
- 1.3. Etiology
- 1.4. Diagnosis
- 1.5. Etiology
- 1.6. Treatment Algorithm
- 1.7. Treatment Options

### **2. FEATURED NEWS AND PRESS RELEASES, 2018-2019**

### **3. LIST OF COMPANIES DEVELOPING LATESTAGE CHRONIC KIDNEY DISEASE (CKD)**

### **4. TREATMENT ALGORITHM**

### **5. CURRENT UNMET NEEDS**

### **6. MARKET TRENDS**

### **7. PIPELINE THERAPEUTICS**

### **8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES** **9. LATE STAGE PRODUCTS (PHASE III)**

#### 9.1 Veverimer

- 9.1.1. Product Description
- 9.1.2. Research and Development
- 9.1.3. Product Development Activities

#### 9.2. jtz-951

- 9.2.1. Product Description
  - 9.2.2. Research and Development
  - 9.2.3. Product Development Activities
- #### 10. Mid Stage Products (Phase II)

#### 10.1 KBP-5074

- 10.1.1. Product Description
- 10.1.2. Research and Development

- 10.1.3. Product Development Activities
- 10.2. Ziltivekimab
  - 10.2.1. Product Description
  - 10.2.2. Research and Development
  - 10.2.3. Product Development Activities

## **11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)**

- 11.1 Finerenone
  - 11.1.1. Product Description
  - 11.1.2. Research and Development
  - 11.1.3. Product Development Activities
- 11.2. Bemethyl
  - 11.2.1. Product Description
  - 11.2.2. Research and Development
  - 11.2.3. Product Development Activities

## **12. DRIVERS OF LATESTAGE CHRONIC KIDNEY DISEASE (CKD)**

## **13. CONSTRAINTS OF LATESTAGE CHRONIC KIDNEY DISEASE (CKD)**

## **14. THERAPEUTIC ASSESSMENT**

- 14.1. Assessment by Route of Administration
- 14.2. Assessment by Phase & Route of Administration
- 14.3. Assessment by Molecule Type
- 14.4. Assessment by Phase & Molecule type
- 14.5. Assessment by Target
- 14.6. Assessment by Mechanism of Action

## **15. COLLABORATIONS AND ACQUISITIONS DETAILS**

## **16. DORMANT PRODUCTS**

## **17. DISCONTINUED PRODUCTS**

## **18. MARKET TRENDS**

## **19. MARKET OPPORTUNITY ASSESSMENT**

**20. UNMET NEEDS**

**21. SWOT ANALYSIS**

**22. APPENDIX**

**23. REPORT METHODOLOGY**

**24. CONSULTING SERVICES**

**25. DISCLAIMER**



## List Of Tables

### LIST OF TABLES

Table 1: Marketed Latestage chronic kidney disease (CKD) drugs, 2019

Table 2: Sales of Marketed drugs

Table 3: Patent expiration details – marketed drugs

Table 4: Number of Products Under Development for Latestage chronic kidney disease (CKD)

Table 5: Products under Development by Companies

Table 6: Late Stage Products

Table 7: Mid Stage Products

Table 8: Early Stage Products

Table 9: Pre-Clinical and Discovery Products

Table 10: Assessment by Route of Administration

Table 11: Assessment by Stage and Route of Administration

Table 12: Assessment by Molecule Type

Table 13: Assessment by Stage and Molecule Type

Table 14: Assessment by Target

Table 15: Assessment by Mechanism of Action

Table 16: Dormant Products

Table 17: Discontinued Products

## List Of Figures

### LIST OF FIGURES

Figure 1: Marketed and Pipeline Latest stage chronic kidney disease (CKD) - Pipeline Review, 2019 drugs, 2019

Figure 2: Sales of Marketed drugs

Figure 3: Patent expiration details – marketed drugs

Figure 4: Number of Products Under Development for Latest stage chronic kidney disease (CKD) - Pipeline Review, 2019

Figure 5: Products under Development by Companies

Figure 6: Late Stage Products

Figure 7: Mid Stage Products

Figure 8: Early Stage Products

Figure 9: Pre-Clinical and Discovery Products

Figure 10: Assessment by Route of Administration

Figure 11: Assessment by Stage and Route of Administration

Figure 12: Assessment by Molecule Type

Figure 13: Assessment by Stage and Molecule Type

Figure 14: Assessment by Target

Figure 15: Assessment by Mechanism of Action

Figure 16: Dormant Products

Figure 17: Discontinued Products

## I would like to order

Product name: Latestage chronic kidney disease (CKD) - Pipeline Review, 2019

Product link: <https://marketpublishers.com/r/L321BA4FB971EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L321BA4FB971EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970